




# E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL)



**Stratification**  
0-2 vs 3-7 adverse factors\*  
Locally extensive vs Stage III/IV




ABVD	Dosage
Doxorubicin	25 mg/m <sup>2</sup> IV días 1 y 15
Bleomycin	10 u/m <sup>2</sup> IV días 1 y 15
Vinblastine	6 mg/m <sup>2</sup> IV días 1 y 15
Dacarbazine	375 mg/m <sup>2</sup> IV días 1 y 15

Stanford V	Dosage
Doxorubicin	25 mg/m <sup>2</sup> IV weeks 1, 3, 5, 7, 9 and 11
Vinblastine	6 mg/m <sup>2</sup> IV weeks 1, 3, 5, 7, 9 and 11
Nitrogen mustard	6 mg/m <sup>2</sup> IV weeks 1, 5, and 9
Etoposide	60 mg/m <sup>2</sup> x2 V weeks 3, 7, and 11
Vincristine	1.4 mg/m <sup>2</sup> IV weeks 2, 4, 6, 8, 10 and 12
Bleomycin	5 u/m <sup>2</sup> IV weeks 2, 4, 6, 8, 10 and 12
Prednisone	40 mg q other day x 12 weeks (Taper week 10-12)



## E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL)



**ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.**

# Treatment of Advanced Hodgkin Lymphoma: The More Things Change, the More They Stay the Same



Longo DL. J Clin Oncol DOI:10.1200/JCO.2012.44.7235